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LETTERS TO THE EDITORRegarding “Cilostazol reduces restenosis after
endovascular therapy in patients with
femoropopliteal lesions”
We were delighted to read the recent publication by Iida et al1
showing that cilostazol significantly reduces restenosis in patients
with femoropopliteal lesions after endovascular therapy. When
looking closely at their results with a view to applying them to our
practice in England, we have a few questions.
Evaluating their patient demographics, we were surprised with
the high preponderance of vascular disease amongst the women
(72.4%). It is well known that the incidence of peripheral artery
disease is greater in men,2 particularly in the western world. Also
the percentages of patients with hypercholesterolemia (52% and
53%) andwhowere taking a statin (30% and 34%) weremuch lower
than in our vascular patient population.
Our next question concerns the duration that patients were
receiving statins. Were these patients newly commenced on statins
during the study initiation? It is well documented that statins have
a cumulative effect, so the earlier they are started, the better the
results.3,4 Also, was subgroup analysis performed with respect to
restenosis to compare those patients who were receiving a statin
and cilostazol with those who were only receiving cilostazol and
not a statin?
All adverse events were shown to be significantly lower in the
cilostazol group. However, it would be interesting to know if there
are any significant differences between the two groups if the actual
adverse effects are broken down. Comparing amputation rates, we
noticed a higher rate in the cilostazol group compared with the
ticlopidine group, was this difference significant? The dropout
rate of patients taking cilostazol was greater than that in the
ticlopidine group, also, was this difference significant?
Analyzing interventional procedures, there appear to be 18
patients who have not had any stents inserted. Did these patients
have isolated angioplasty? If so, have they been intentionally in-
cluded in the study population and has subgroup analysis been
performed, for this group of patients, comparing results between
the cilostazol and ticlopidine groups?
We felt that this study is important, because it is the first
prospective study of the effects of cilostazol and ticlopidine on
restenosis in femoropopliteal lesions, but caution should be taken
when applying these results to all practices.
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Reply
We thank Dr Sharma and his colleagues for their interest in
our article and appreciate their taking the time to address this
important correspondence. We would like to respond to the sev-
eral comments they have made. As Dr Sharma correctly points out,
the patient demographics in our article included an inadvertent
error regarding gender. We misplaced male with female in our
manuscript. Indeed, most of the patients weremen: 70% (44 of 63)
in the cilostazol group and 75% (48 and 64) in the ticlopidine
group, which is similar to the Western world.
The comments raised by the correspondents regarding statins
are interesting. It is true that relatively fewer patients were taking
statins compared with the Western populations. Unlike in North
America and Europe, our vascular patient population did not
include many of the severest forms of hypercholesterolemia. In
fact, the average low-density lipoprotein level was 114 mg/dL in
the cilostazol group and 119 mg/dL in the ticlopidine group.
We additionally analyzed the duration of statin therapy, which
was not significantly different between the cilostazol and the
ticlopidine groups (data not shown). Subgroup analysis has also
been performed to compare those taking statins and cilostazol and
those taking cilostazol without statins.
Restenosis and primary patency rates at 12, 24, and 36months
were not significantly different between the groups (data not
shown). These rates may be different in vascular patient popula-
tions with more severe forms of hypercholesterolemia in Western
countries.
Adverse events in this study included death, amputation, and
restenosis, which were broken down, respectively, as 4, 4, and 15 in
the cilostazol group and 6, 1, and 27 in the ticlopidine group.
These adverse events were significantly infrequent in the cilostazol
group compared with the ticlopidine group, as shown by Kaplan-
Meier survival with log-rank testing (Fig 4).
Regarding the interventional procedures, frequencies of stent
use were similar between the cilostazol group (89%, 56 patients)
and the ticlopidine group (84%, 54 patients). Seventeen patients
who did not have stents were treated with angioplasty alone.
Among these, patency rates were similar between the cilostazol
group (89%, 74%, and 74% at 12, 24, and 36 months) and the
ticlopidine group (75%, 63% and 63% at 12, 24, and 36 months,
P  .53).
Thus, we believe the conclusion reached in our article, that
cilostazol contributed to the reduction of restenosis rate, particu-
larly after the endovascular therapy using self-expanding stents,
remains valid, at least in our vascular patient population.
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